Company Shares of SciClone Pharmaceuticals Drops by -1.03%

SciClone Pharmaceuticals (NASDAQ:SCLN) has tumbled 1.03% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 7.58% in the last four weeks. In the past week, the company has outperformed the S&P 500 by 0.16% and the outperformance has advanced to 6.59% for the last 4 weeks period.

SciClone Pharmaceuticals (NASDAQ:SCLN): The stock opened at $14.69 on Friday but the bulls could not build on the opening and the stock topped out at $14.93 for the day. The stock traded down to $13.48 during the day, due to lack of any buying support eventually closed down at $13.49 with a loss of -7.86% for the day. The stock had closed at $14.64 on the previous day. The total traded volume was 2,028,067 shares.

The company shares have rallied 42.30% from its 1 Year high price. On Jun 15, 2016, the shares registered one year high at $15.03 and the one year low was seen on Sep 28, 2015. The 50-Day Moving Average price is $13.34 and the 200 Day Moving Average price is recorded at $10.59.

On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (President & CEO) of Sciclone Pharmaceuticals Inc, Blobel Friedhelm had sold 10,000 shares worth of $92,900 in a transaction dated March 28, 2016. In this transaction, 10,000 shares were sold at $9.29 per share.

Currently the company Insiders own 6.95% of SciClone Pharmaceuticals shares according to the proxy statements. Institutional Investors own 79.03% of SciClone Pharmaceuticals shares.

SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments, including China and the rest of the world (the United States and Hong Kong). The Companys lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin, therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc, a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex, a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications, and RapidFilm, an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.